BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37818718)

  • 1. H3K27M mutant glioma: Disease definition and biological underpinnings.
    Saratsis AM; Knowles T; Petrovic A; Nazarian J
    Neuro Oncol; 2024 May; 26(Supplement_2):S92-S100. PubMed ID: 37818718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas.
    Mosaab A; El-Ayadi M; Khorshed EN; Amer N; Refaat A; El-Beltagy M; Hassan Z; Soror SH; Zaghloul MS; El-Naggar S
    Sci Rep; 2020 May; 10(1):8368. PubMed ID: 32433577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
    Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
    Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    Vuong HG; Ngo TNM; Le HT; Dunn IF
    J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
    Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
    Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review.
    Mohiuddin S; Maraka S; Usman Baig M; Gupta S; Muzzafar T; Valyi-Nagy T; Lindsay H; Moody K; Razvi S; Paulino A; Slavin K; Gondi V; McCutcheon I; Zaky W; Khatua S
    J Clin Neurosci; 2021 Jul; 89():405-411. PubMed ID: 34053821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
    Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
    Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone H3 K27M mutations in adult cerebellar high-grade gliomas.
    Nakata S; Nobusawa S; Yamazaki T; Osawa T; Horiguchi K; Hashiba Y; Yaoita H; Matsumura N; Ikota H; Hirato J; Yoshimoto Y; Yokoo H
    Brain Tumor Pathol; 2017 Jul; 34(3):113-119. PubMed ID: 28547652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone-mutant glioma presenting as diffuse leptomeningeal disease.
    Nadkarni T; Hamilton K; Niazi F; Ward M; Okakpu U; Castellani RJ; Prisneac I; Sener U
    CNS Oncol; 2021 Sep; 10(3):CNS75. PubMed ID: 34469205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy.
    Graham MS; Mellinghoff IK
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
    Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
    Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
    Wang Q; Niu W; Pan H
    Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
    Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
    Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.